Skip to Content

'
Jatin J. Shah, MD

Present Title & Affiliation

Primary Appointment

Assistant Professor, Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas, M. D. Anderson Cancer Center, Houston, TX

Education & Training

Degree-Granting Education

2001 Ohio State University College of Medicine, Columbus, OH, MD, Medicine
1997 Ohio State University, Columbus, OH, BS, Mechanical Engineering

Postgraduate Training

7/2004-6/2007 Clinical Fellowship, Hematology/Oncology, University of Alabama at Birmingham, Birmingham, AL, James Foran
7/2002-6/2004 Clinical Residency, Internal Medicne, Cleveland Clinic Foundation, Cleveland, OH, Craig Neilsen
7/2001-6/2002 Clinical Internship, Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, Craig Neilsen

Board Certifications

11/2007 American Board of Internal Medicine, Hematology
11/2007 American Board of Internal Medicine, Oncology
8/2004 American Board of Internal Medicine

Experience/Service

Administrative Appointments/Responsibilities

Member, Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas, M. D. Anderson Cancer Center, Houston, TX, 2007-present

Institutional Committee Activities

Member, Multiple Myeloma Tissue Bank Steering Committee, Department of Lymphoma/Myeloma, Division of Cancer Medicine, 2007-present

Honors and Awards

2007 Outstanding Research Fellow, University of Alabama at Birmingham
2006 Southern Society of Clinical Investigation Young Investigator Award
1993 Alpha Lambda Delta, Freshman Honor Society
1993 Phi eta Sigma, Freshman Honor Society
1992 Leadership Ohio State, Freshman Foundation Scholarship

Professional Memberships

American Association of Cancer Research
Member, 2006-present
American College of Physician- American Society of Internal Medicine
Member, 2001-present
American Medical Association
Member, 1997-present
American Society of Clinical Oncology
Member, 2004-present
American Society of Hematology
Member, 2004-present
American Society of Mechanical Engineers
Member, 2004-present
National Associations of Inpatient Physicians
Member, 2001-present
Ohio State Medical Association
Member, 1997-2001
SWOG
Member, 6/2008-present

Selected Publications

Peer-Reviewed Original Research Articles
1. Shah JJ, Kuhn DJ, Orlowski RZ. Bortezomib and EGCG: no green tea for you? Blood 113(23):5695-6, 6/2009. PMCID: PMC2700310.
2. Shah JJ, Orlowski RZ, Thomas SK. Role of combination bortezomib and pegylated liposomal doxorubicin in the management of relapsed and/or refractory multiple myeloma. Ther Clin Risk Manag 5(1):151-9, 2/2009. e-Pub 3/2009. PMCID: PMC2697512.
3. Shah J., Wang W, Harrough VD, Saville W, Meredith R, Shen S, Mueh J, Lister S, Jasthy G, Maggass C, McKay R, Krumdieck M, Tharp C, Winter S, Gregory W, Buchholz S, Awasthi S, Jacobs H, Chung J, Egner AF, Lobuglio and Forero A. Retreatment with yttrium-90 ibritumomab tiuxetan in patients with B-cell non-Hodgkin's lymphoma. Leuk Lymphoma 48(9):1736-44, 2007.
4. Forero A, Shah J, Carlisle R, Triozzi Pl, LoBuglio AF. Wang WQ, Fujimori M, and Conry RM. A phase I study of an anti-GD3 monoclonal antibody, KW-2871, in patients with metastatic melanoma. Cancer Biother Radiopharm 21(6):561-8, 2006.
5. Triozzi PL, Shah JJ, Wang WQ, Aldrich W, Edberg JC, Su K, Carlisle K, Conry R, LoBuglio AF, and Forero C. Anti-GD3 monoclonal antibody effects on lymphocytes and antibody-dependent cellular cytotoxicity. Cancer Biother Radiopharm 21(6):553-60, 2006.
6. Shah JJ, Meredith R, Shen S, Nabors B, Lobuglio A, Yester M, Forero A. Case report of a patient with primary central nervous system lymphoma treated with radioimmunotherapy. Clin Lymphoma Myeloma 7(3):236-238, 2006.
7. Mace SE, Shah J. Observation medicine in emergency medicine residency programs. Acad Emerg Med 9(2):169-171, 2002.
8. Wen H, Shah J, and Balaban RS. Hall effect imaging. Biomed Eng 45(1):119-124, 1998.

Abstracts
1. J. Shah, S. Donegan, D. Wang, F. Robert. Incidence of Venous Thromboembolic Events and Effect on Survival in Patients with Lung Cancer. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I 25(18s) (June 20 Supplement) (#18017), 2007.
2. J Shah, J Mueh, J Lister, et al. Safety and Efficacy of retreating follicular NHL with 90 Y Ibritumomab Tiuxetan (Zevalin). Journal of Investigative Medicine 55(1) (#330), 2007.
3. J. Shah, A. Forero, R. Carlisle, et al. Phase 1 Study of an Anti-GD3 Monoclonal Antibody, (KW-2871) in patients with Advanced Metastatic Melanoma. Journal of Investigative Medicine 54(1) (#189), 2006.
4. J. Shah, D. Harrough, W. Saville, et al. Safety and efficacy of retreating follicular non-Hodgkin's lymphoma (NHL) with 90Y ibritumomab tiuxetan. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part I 24(18s) (June 20 Supplement) (#17528), 2006.
5. A. Forero-Torres, J. Shah et. al. A Preliminary Report of a Phase I Study of Zevalin® Using a Modified Treatment Regimen for Relapsed or Refractory CD20+ B-Cell Follicular or Transformed Non-Hodgkin’s Lymphoma (NHL). Blood 106 (#4798), 2005.
6. J. Shah, A. Forero, R. Carlisle, P. Triozzi, A. Lobuglio, T. Kuwabara, A. Teitelbaum, M. Fujimori, M. Conry. Phase 1 Study of an Anti-GD3 Monoclonal Antibody, (KW-2871) in patients with Advanced Metastatic Melanoma. Journal of Clinical Oncology 23(16s) part I of II (June 1 Supplement) (#2556), 2005.
7. J. J. Shah, M. P.V. Gomes, S. R. Deitcher. Thromboelastographic (TEG) Characterization of Patients with Hematologic Malignancy and Chemotherapy Induced Thrombocytopenia (CIT). Blood 104 (#2729), 2004.
8. J. J. Shah, T. Mekhail, C. Comb, A. Leschinsky, C. Moon, P. Rayman, P. Elson, J. Finke, R. M. Bukowski. Renal cell cancer: Correlation of tumor characteristics with peripheral blood T cell NFκB activation and activation induced cell death (AICD). Proc Am Soc Clin Oncol 22:440 (#1766), 2003.
9. MN Saleh, I Percent, TE Wood, J Posey III, J Shah, R Carlisle, S Wojtowicz-Praga, A Forero-Torres. A phase I study of CS-1008 (humanized monoclonal antibody targeting death receptor 5 or DR5), administered weekly to patients with advanced solid tumors or lymphoms. ASCO 2008 Annual Meeting (#3537). Submitted.

Manuals, Teaching Aids, Other Teaching Publications
1. Shah J, Richardson P, Mitsaides C. Multiple Myeloma Syllabus: Core Reading Collection for Hematology/Oncology Fellowship, 1/2006.

Grant & Contract Support

Title: Targeting Met Tyrosine Kinase in Multiple Myeloma
Funding Source: Center for Targeted Therapy Disease-Specific Grant in Lymphoma/Myeloma
Role: Co-Investigator
Principal Investigator: Robert Orlowski, MD. PhD
Duration: 4/1/2008

Last updated: 9/18/2009